The White House psychedelics executive order accelerates research, clinical trials and “Right to Try” access for drugs like psilocybin, MDMA and ibogaine.
Source: US Top News and Analysis
Related Posts
If a violent downturn strikes the market, new ETF strategies may be vulnerable. Here’s why
Innovation in the exchange-traded fund industry could come at a cost to investors during extreme…
Is an IRS audit less likely amid agency cuts? Some issues are still ‘low-hanging fruit,’ expert says
There are still some red flags for an IRS audit despite budget and staffing cuts,…
American rejects merger talks with United Airlines
American Airlines said on Friday that it was not interested in a merger with United…